BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Underestimated Metropolitan Experience Urban communities On the planet - 2Extravagance SUVs for Seniors: Solace, Innovation, and Security
- 3'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- 4Vote in favor of your Favored kind of craftsmanship
- 5Young Muslims in Germany feel left out of Mideast debate, experts say
- The Universe of Impeccable Pearls: A Manual for Valuable Gems
- The Most Notable Design Brands of the 21st Hundred years
- Pick Your Favored method of transportation
- Satellites capture aftermath of Ethiopian volcano's 1st eruption in recorded history (images)
- Which Startup's Innovation Could Reform Medical care?
- Living Abroad: Social Inundation and Self-improvement
- The Delight of Perusing: Book Suggestions for Each Kind
- Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- Careful Connections: Building Association and Trust
